ImmuPharma (LON:IMM) Trading Up 34.1% - Should You Buy?

Key Points

• ImmuPharma shares surged 34.1% during trading, reaching a last traded price of GBX 10.81 ($0.15) compared to the previous close of GBX 8.06 ($0.11).
• The company's stock saw a substantial trading volume increase, with approximately 57.6 million shares changing hands, a 656% rise from its average daily volume.
• ImmuPharma reports a negative earnings per share of GBX (0.38) for its last quarter, and analysts forecast a troubling -339.0000022 EPS for the current fiscal year.

ImmuPharma plc (LON:IMM - Get Free Report) shares rose 34.1% during mid-day trading on Wednesday . The stock traded as high as GBX 11.50 ($0.16) and last traded at GBX 10.81 ($0.15). Approximately 57,593,953 shares were traded during mid-day trading, an increase of 656% from the average daily volume of 7,620,919 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Stock Performance

The firm's 50 day moving average is GBX 3.12 and its 200-day moving average is GBX 2.92. The stock has a market capitalization of £69.86 million, a price-to-earnings ratio of -1,570.67 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, sell-side analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.